A positive margin means cancer cells were found right at the cut edge of the tissue removed during surgery.It appears in the histopathology report, and it’s often the single line patients worry about most.It doesn’t automatically mean the cancer has spread or come back. It means the surgeon can’t be sure every cancer cell was removed.
What happens next depends on the cancer type, which edge is involved and how much of it is affected.

According to Prof. Dr. Sandeep Nayak, a surgical oncologist who reviews surgical margins on pathology reports after every resection, “A positive margin is a finding, not a verdict. It tells us where to look more carefully. Sometimes we go back and take more tissue. Sometimes radiation or close follow up is the better answer. The mistake is treating every positive margin the same way.”

The pathologist inks the outer surface of the removed tissue, then checks under the microscope how close the cancer comes to it.

Positive: Cancer cells touch the inked edge. Some disease may still be left behind in the body.

Close: Cancer cells sit near the edge without touching it. How near counts as too near varies by cancer type.

Clear: No cancer cells at the edge. This suggests the whole tumour was taken out.

Focal or extensive: A tiny spot of involvement is handled differently from cancer reaching the edge in several places.

Which edge is involved matters as much as the label, so the report is read alongside the operation notes. Our page on surgical oncology consultation covers how that review is done.

There isn’t one standard answer. The options below are weighed against each other.

Re-excision: A second operation to remove more tissue from the involved edge. It’s common after breast conserving surgery, where a positive margin roughly doubles the risk of local recurrence.

Radiation: In selected breast cases with a small, focal positive margin, an extra radiation dose to the surgical site may be used instead of another operation.

Close monitoring: Some situations start with scans and tests rather than surgery. After partial nephrectomy, for example, surveillance is often the first step.

Tumour board review: Margin status, tumour type and grade are discussed together. Re-excision isn’t routine for every patient, and research supports a selective approach.

The basics, including what a margin is and how wide it should be, are covered in our blog on what a surgical margin is in cancer surgery.

Surgery remains the standard and primary DCIS treatment, though it isn’t compulsory in every single situation.
Most patients are advised lumpectomy with radiation or a mastectomy, because DCIS can occasionally progress into invasive breast cancer.
For a carefully selected group with low-risk disease, clinical trials are now studying close monitoring instead of immediate surgery.
That approach is still being tested, so it isn’t yet a routine option outside a structured plan.

According to Prof. Dr. Sandeep Nayak, a surgical oncologist who guides patients through DCIS treatment decisions, “DCIS isn’t an emergency, but it isn’t something to ignore either. We can’t yet tell which cases will turn invasive and which will stay put. That’s why surgery stays the standard. Monitoring is a promising idea for the right patient, and it belongs in a proper study or a carefully supervised plan, not a casual decision.”

DCIS sits inside the milk ducts and hasn’t spread into surrounding tissue. Even so, removal is the usual advice.

Unpredictable behaviour: There’s no reliable way yet to tell which DCIS will become invasive. Removing it takes the guesswork out.

Lumpectomy with radiation: The area is removed with a margin of healthy tissue, and radiation afterward roughly halves the chance of local recurrence.

Mastectomy: Advised when DCIS is widespread, sits in more than one area, or is large for the size of the breast. Radiation usually isn’t needed after it.

Hormone therapy: If the DCIS is hormone receptor positive, tamoxifen or an aromatase inhibitor may follow surgery to lower the risk of it returning.

Which route fits depends on how far the DCIS extends on imaging and what the biopsy shows. Our page on breast cancer treatment explains how that assessment is made.

In a small, selected group, possibly. The evidence is still building.

Active monitoring: Regular mammograms and clinical exams in place of an immediate operation. This is being tested in the COMET, LORIS, LORD and LORETTA trials.

Who qualifies: Low risk disease only. Low or intermediate grade, found on screening, no sign of invasion, and usually hormone receptor positive in a woman over 40.

What early results show: In COMET, women who chose monitoring didn’t have more invasive cancer at two years. Longer follow up is still awaited.

Why caution remains: A biopsy can miss a hidden invasive area. In some studies, a minority of women who looked suitable for monitoring had invasive cancer found at surgery.

Drug treatment is a related question for hormone positive disease. Our blog on hormone therapy vs surgery in HR positive breast cancer covers where each one fits.

Prof. Dr. Sandeep Nayak has over 24 years in surgical oncology, with deep experience in breast cancer surgery, both breast conserving and mastectomy. DNB in Surgical Oncology and General Surgery. MRCS from the UK. A fellowship in Laparoscopic and Robotic Onco Surgery too. He chairs Oncology Services across Karnataka and serves as Executive Director of Surgical Oncology and Robotic Surgery at KIMS Hospital, Bangalore. Every case is reviewed at the tumour board, where imaging, biopsy grade and receptor status are weighed together before a plan is set.

DCIS decisions are rarely one size fits all. The extent on imaging, the grade and the patient’s own priorities all shape the advice. Call +91 9482202240 to book your consultation.

References

1. National Center for Biotechnology Information — Ductal Carcinoma In Situ of the Breast: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407624/
2. National Center for Biotechnology Information — Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial: https://pmc.ncbi.nlm.nih.gov/articles/PMC11920841/

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

A partial nephrectomy removes only the tumour along with a thin margin of healthy tissue, leaving the rest of the kidney working.
A radical nephrectomy takes out the whole kidney, usually with the surrounding fat and, in some cases, nearby lymph nodes.
Where the tumour is small and well placed, preserving the kidney is generally preferred, since it protects long term kidney function.
Larger or more complex tumours, and those reaching into the main vessels, often leave radical removal as the safer route.

According to Prof. Dr. Sandeep Nayak, a surgical oncologist who performs robotic and laparoscopic partial nephrectomy for kidney cancer, “Patients often think removing the whole kidney is the safer cancer operation. For a small tumour, it usually isn’t. Cancer control is comparable, and saving the kidney protects you for decades. The tumour’s size and position decide what’s possible, not the label on the operation.”

Sparing the kidney is preferred whenever it can be done safely. Several things decide whether it can.

Tumour size. Smaller tumours, especially under 4 cm, are the classic candidates. Larger ones are sometimes still manageable, depending on position.

Tumour position. A tumour sitting on the outer surface is far easier to remove cleanly than one buried deep near the central collecting system.

Kidney function. In patients with one kidney, tumours in both kidneys, or existing kidney disease, saving as much tissue as possible matters even more.

Surgical approach. Robotic and laparoscopic techniques allow precise removal of the tumour with small incisions and a faster return to normal activity.

Whether a kidney can be saved is worked out from imaging before surgery, not decided on the table. Our page on kidney cancer treatment covers how that evaluation is done.

Radical nephrectomy isn’t a default. It’s chosen when keeping any part of the kidney isn’t safe or technically possible.

Large tumours. Bigger masses often leave too little healthy kidney to preserve, so the whole organ comes out with the surrounding fat.

Central location. Tumours close to the main vessels and collecting system can make a partial removal unsafe, even when the tumour itself is not especially large.

Vein involvement. When cancer has grown into the renal vein, or further toward the main vein leading to the heart, complete removal is needed.

Lymph node spread. Nearby nodes that are involved may be taken out along with the kidney as part of an extended procedure.

The remaining kidney carries the load afterward, which is why most people do well with one. Our blog on radical nephrectomy surgery explains when and how that operation is carried out.

Prof. Dr. Sandeep Nayak brings over 24 years of surgical oncology experience to kidney cancer care, including robotic and laparoscopic partial and radical nephrectomy. He holds DNB qualifications in Surgical Oncology and General Surgery, an MRCS from the UK, and a fellowship in Laparoscopic and Robotic Onco Surgery. He currently serves as Chairman of Oncology Services across Karnataka and Executive Director of Surgical Oncology and Robotic Surgery at KIMS Hospital, Bangalore. Every case is reviewed at the tumour board, with a clear lean toward sparing the kidney wherever it can be done without compromising cancer control.

The choice between the two operations affects kidney function for years afterward, not just cancer control. That’s why the decision is made on imaging and tumour detail, before the date for surgery is fixed. Call +91 9482202240 to book your consultation.

References

1. National Center for Biotechnology Information — Partial vs Radical Nephrectomy for T1–T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes: https://pmc.ncbi.nlm.nih.gov/articles/PMC5274548/
2. National Center for Biotechnology Information — Comparison of Partial and Radical Nephrectomy for pT1b Renal Cell Carcinoma: https://pmc.ncbi.nlm.nih.gov/articles/PMC2941807/

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

A histopathology report provides important information about a cancer diagnosis, including the tumour type, grade, margins, lymph node involvement, and TNM stage. TNM staging describes the extent of cancer by assessing the primary tumour (T), nearby lymph nodes (N), and whether the cancer has spread to distant parts of the body (M). Understanding these sections can help patients interpret their report and discuss the results more clearly with their doctor.

According to Prof. Dr. Sandeep Nayak, a surgical oncologist who reviews TNM staging codes on pathology reports daily, “Patients read the diagnosis line. Then stop. That’s the mistake. Grade, margins, lymph node count, all of it shapes the treatment plan, not just that one word at the top. I’d rather sit with a patient and go through their own report than send them home with a label and nothing else.”

A pathology report follows a fairly consistent structure, even though the medical terms inside it vary by cancer type.

Gross description. What the tissue sample actually looked like, physically, before anyone put it under a microscope. Size, weight, colour, any visible masses.

Microscopic description. How the cells look once magnified. This includes differentiation, basically how much the cancer cells still resemble normal ones.

Tumour grade. A score for how abnormal the cells look, and how fast the cancer’s likely to grow. Says nothing about how far it’s spread though.

Margins and lymph nodes. Did cancer cells reach the cut edge of the tissue. How many lymph nodes were checked, and how many came back positive.

Making sense of all this, alongside imaging, is really what a full evaluation comes down to. Our page on surgical oncology consultation covers how that gets put together.

T, N and M each answer a different question, with a number attached to each.

T for tumour. A number, 1 through 4, for the size and local extent of the tumour. Tis marks very early, non-invasive disease.

N for nodes. Whether nearby lymph nodes contain cancer. N0 means none, higher numbers mean more spread.

M for metastasis. M0, no distant spread found. M1, the cancer’s reached other organs.

Clinical versus pathological staging. Lowercase c before TNM means staging from scans and exams. Lowercase p means it’s confirmed from tissue after surgery.

Staging doesn’t end at the report. It directly shapes what surgery can and can’t do. Our blog on cancer staging and how it determines surgery goes further into that connection

Prof. Dr. Sandeep Nayak has over 24 years in surgical oncology. Much of it spent turning complex pathology findings into treatment plans patients can actually follow. DNB, Surgical Oncology and General Surgery. MRCS from the UK. A fellowship in Laparoscopic and Robotic Onco Surgery too. He chairs Oncology Services across Karnataka now, and serves as Executive Director of Surgical Oncology and Robotic Surgery at KIMS Hospital, Bangalore. Every case goes through full tumour board review. Imaging, pathology, clinical findings, discussed together. Never read in isolation.

Patients get walked through their own report in plain language here, not handed a diagnosis line and left to figure out the rest alone. Call +91 9482202240 to book your consultation.

References

1. National Cancer Institute — Pathology Reports Fact Sheet: https://cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet
2. National Center for Biotechnology Information — Clinical and Pathological Staging Discrepancies in Laryngeal Cancer: A Systematic Review: https://pmc.ncbi.nlm.nih.gov/articles/PMC11815896/

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.

The main difference is how many lymph node groups and surrounding structures are removed. Selective neck dissection removes only the lymph node levels most likely to contain cancer, while modified radical neck dissection removes lymph nodes from levels I to V while preserving key structures when possible. The choice depends on the tumour location, lymph node involvement, and extent of disease.

According to Prof. Dr. Sandeep Nayak, a surgical oncologist with extensive experience across different types of neck dissection, “Patients often assume more extensive surgery means safer surgery. That’s not quite how it works here. Selective dissection, done on the right case, achieves the same oncological goal with far less impact on shoulder function. Modified radical becomes necessary only when the disease genuinely demands clearing every level.”

Selective neck dissection targets only the node groups most likely to harbour disease, based on where the primary tumour sits.

Node levels removed. Only the specific levels at risk, often I through III for oral cavity cancer, rather than the full five-level spread.

Structures preserved. The jugular vein, accessory nerve and sternocleidomastoid muscle all stay intact, since the procedure never touches them to begin with.

Shoulder function. Recovery tends to be faster and more complete here, though some degree of dysfunction can still occur from nerve retraction during surgery.

Typical use. Most often used for early stage disease with no confirmed spread, sometimes as a staging procedure to guide further treatment.

Choosing the right extent of dissection depends heavily on accurate pre-operative staging and imaging. Our page on head and neck cancer treatment covers how that evaluation feeds into the surgical plan.

Modified radical neck dissection clears every lymph node level in the lateral neck while sparing structures a classical radical dissection would remove.

Node levels removed. All five levels, I through V, come out, a far broader clearance than a selective approach.

Structures preserved. One or more of the jugular vein, accessory nerve and sternocleidomastoid muscle are spared, depending on how the disease has spread.

Shoulder function. Dysfunction is more common and more pronounced here, largely because level V dissection affects the nerve more directly.

Typical use. Reserved for confirmed or extensive nodal disease, where the risk of leaving untreated nodes outweighs the added surgical impact.

Deciding between these approaches isn’t something patients work out from a diagnosis alone. Our blog on neck dissection surgery for cancer covers the broader picture of when neck dissection gets recommended in the first place.

Dr. Sandeep Nayak has spent over 24 years in robotic and minimally invasive cancer surgery, head and neck tumors included. His training in robotic technique means he can reach and remove tumors through the mouth without disturbing much of the surrounding muscle or tissue. That precision is the whole point.

Patients under his care generally get back to normal swallowing and speech faster than with open surgery. Less visible scarring too, and a shorter hospital stay. Recovery still depends on tumor size and where exactly it sits, but the outcomes hold up. No exaggeration needed here.

References

1. National Center for Biotechnology Information — Shoulder Dysfunction and Quality of Life Following Modified Radical and Selective Neck Dissection: A Prospective Comparative Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC11306493/
2. National Center for Biotechnology Information — Impact of Modified Radical Neck Dissections on the Number of Retrieved Nodes, Recurrence and Survival: https://pmc.ncbi.nlm.nih.gov/articles/PMC9442232/

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.